Bicycle Therapeutics Delivers Promising Pipeline Update at AACR 2026: Key Advancements in Nuzefatide Pevedotin and EphA2 Programs

CAMBRIDGE, UK & BOSTON, April 20, 2026 – Bicycle Therapeutics plc (NASDAQ: BCYC), a pioneer in next-generation therapeutics based on proprietary bicyclic peptide technology, has made several significant announcements regarding its EphA2-targeted pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026. These updates include positive clinical and preclinical data, critical dose escalation insights, and meaningful progress in the company’s radiopharmaceutical platform. The disclosures are likely to be closely monitored by investors and could have a material impact on the company’s valuation and share price.

Key Highlights

• Encouraging Efficacy and Safety Data for Nuzefatide Pevedotin:
  • Phase 1/2 data on nuzefatide pevedotin (formerly BT5528), an EphA2-targeting Bicycle® Drug Conjugate (BDC®), in combination with nivolumab in previously treated metastatic urothelial cancer (mUC) patients, showed a 40% confirmed overall response rate (ORR) among patients with EphA2+ tumors and a 100% ORR among those who were monomethyl auristatin E (MMAE)-naïve.
  • Patients achieving partial response or stable disease for at least 16 weeks remained on treatment for a minimum of 56 weeks, with most still undergoing therapy at the data cut-off.
  • The combination was generally well tolerated, with no Grade ≥3 treatment-related adverse events of clinical interest and no hemorrhagic events. Only one dose-limiting toxicity (Grade 3 fatigue) was reported, which resolved without dose reduction.
• Preferred Dose Identified for Monotherapy and Start of Phase 2 in PDAC:
  • Dose range finding studies have established 8mg/m² every two weeks (Q2W) as the preferred monotherapy dose for nuzefatide pevedotin.
  • The company successfully dosed the first patient in a Phase 2 trial for second-line and later (2L+) recurrent pancreatic ductal adenocarcinoma (PDAC) in April 2026.
  • The trial aims to address a substantial unmet need, as PDAC patients have very limited treatment options.
• Human Imaging Data Validates EphA2 as a Novel Cancer Target:
  • Imaging studies using a gallium-68 labelled Bicycle Imaging Agent (BIA) targeting EphA2 in PDAC patients demonstrated rapid tumor uptake, efficient excretion, and successful detection of multiple metastatic sites in the majority of patients.
  • Data from 15 out of 18 imaged patients supports the potential of EphA2 as a valuable oncology target and showcases the translational capability of Bicycle’s radioligand platform for both therapy and imaging.
• Robust Preclinical Efficacy in PDAC and HNSCC Models:
  • Preclinical studies in 16 patient-derived xenograft (PDX) models of PDAC demonstrated universal EphA2 expression; 10 of 14 tested models responded to nuzefatide, with six showing high sensitivity.
  • Strong anti-tumor activity was also confirmed in cell-line-derived xenograft (CDX) models of head and neck squamous cell carcinoma (HNSCC), further broadening the potential clinical utility of nuzefatide pevedotin.
• Strategic Pipeline Progression and Next Steps:
  • Bicycle Therapeutics is leveraging these data to prioritize nuzefatide pevedotin development in pancreatic cancer and to advance a next-generation pipeline of EphA2-targeted radiotherapeutics for bladder and other EphA2-expressing tumors.
  • Ongoing and future clinical development plans, as well as additional imaging data, will be closely watched and could further influence market expectations.

Shareholder-Relevant and Potentially Price-Sensitive Information

• Demonstration of clinical efficacy and favorable safety profile for nuzefatide pevedotin in previously hard-to-treat cancer populations may increase investor confidence in the platform and the likelihood of future regulatory success.
• Initiation of a Phase 2 trial in recurrent PDAC, with the first patient dosed, marks a key value inflection point and exposes the company to potential breakthrough therapy designations or partnership interest.
• Human imaging data validating EphA2 as a novel cancer target and the translational capability of the Bicycle platform broadens the addressable market and de-risks future radiopharmaceutical development.
• Preclinical activity in both PDAC and HNSCC models suggests pipeline optionality and potential expansion into multiple tumor types, which may impact long-term valuation.
• The company’s ongoing clinical progress and future data releases are likely to serve as catalysts for share price movement.

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage company developing a new class of therapeutics based on synthetic bicyclic peptides that offer high affinity and selectivity for previously undruggable targets. The company’s pipeline includes nuzefatide pevedotin (EphA2-targeted BDC), zelenectide pevedotin (Nectin-4-targeted BDC), BT7480 (Bicycle TICA targeting Nectin-4 and CD137), and a series of radioconjugates and imaging agents. Bicycle Therapeutics is headquartered in Cambridge, UK, with major operations in Lexington, MA, USA.

Investor Contact

Matthew DeYoung
Argot Partners
[email protected]
212-600-1902

Media Contact

Argot Partners
[email protected]

Disclaimer: This article is based on the most recent disclosures from Bicycle Therapeutics plc and is intended solely for informational purposes. It may contain forward-looking statements, which are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described. Investors should refer to the company’s filings with the SEC for a full discussion of risk factors and should not place undue reliance on forward-looking statements. This article does not constitute investment advice.

View BICYCLE THERAPEUTICS PLC Historical chart here